Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A–MODY cohort

Diabetic Medicine

Volumn 33, Issue 7, 2016, Pages 976-984

  Bacon, S ^a   Kyithar, M P ^a   Rizvi, S R ^a   Donnelly, E ^a   McCarthy, A ^a   Burke, M ^a   Colclough, K ^b   Ellard, S ^b,c   Byrne, M M ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GLICLAZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DIABETIC MACROVASCULAR COMPLICATION; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; EXON; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; GLYCEMIC CONTROL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PHENOTYPE; PROLIFERATIVE RETINOPATHY; WEIGHT GAIN; YOUNG ADULT;

EID: 85028235080     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12992     Document Type: Article

References (27)

1. Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenic beta–cell diabetes. Nat Clin Pract Endocrinol Metab 2008; 4: 200–213.
2. Frayling TM, Bulamn MP, Ellard S, Appleton M, Dronsfield MJ, Mackie AD et al. Mutations in the hepatocyte nuclear factor–1alpha gene are a common cause of maturity-onset diabetes of the young in the U.K. Diabetes 1997; 46: 720–725.
3. Lehto M, Wipemo C, Ivarsson SA, Lindgren C, Lipsanen-Nyman M, Weng J et al. High frequency of mutations in MODY and mitochondrial genes in Scandinavian patients with familial early-onset diabetes. Diabetologia 1999; 42: 1131–1137.
4. Gragnoli C, Cockburn BN, Chiaramonte F, Gorini A, Marietti G, Marozzi G et al. Early-onset Type II diabetes mellitus in Italian families due to mutations in the genes encoding hepatic nuclear factor 1alpha and glucokinase. Diabetologia 2001; 44: 1326–1329.
5. Kyithar MP, Bacon S, Pannu KK, Rizvi SR, Colclough K, Ellard S et al. Identification of HNF1A–MODY and HNF4A–MODY in Irish families: phenotypic characteristics and therapeutic implications. Diabetes Metab 2011; 37: 512–519.
6. Costa A, Bescos M, Velho G, Chevre J, Vidal J, Sesmilo G et al. Genetic and clinical characterisation of maturity-onset diabetes of the young in Spanish families. Eur J Endocrinol 2000; 142: 380–386.
7. Hattersley AT. Maturity-onset diabetes of the young: clinical heterogeneity explained by genetic heterogeneity. Diabet Med 1998; 15: 15–24.
8. Pontoglio M, Sreenan S, Roe M, Pugh W, Ostrega D, Doyen A et al. Defective insulin secretion in hepatocyte nuclear factor 1alpha-deficient mice. J Clin Invest 1998; 101: 2215–2222.
9. Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 2003; 362: 1275–1281.
10. Hansen T, Eiberg H, Rouard M, Vaxillaire M, Moller AM, Rasmussen SK et al. Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation. Diabetes 1997; 46: 726–730.
11. Sovik O, Njolstad P, Folling I, Sagen J, Cockburn BN, Bell GI. Hyperexcitability to sulphonylurea in MODY3. Diabetologia 1998; 41: 607–608.
12. Pearson ER, Liddell WG, Shepherd M, Corrall RJ, Hattersley AT. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor–1alpha gene mutations: evidence for pharmacogenetics in diabetes. Diabet Med 2000; 17: 543–545.
13. Becker M, Galler A, Raile K. Meglitinide analogues in adolescent patients with HNF1A–MODY (MODY 3). Pediatrics 2014; 133: e775–e779.
14. Hattersley A, Bruining J, Shield J, Njolstad P, Donaghue KC. The diagnosis and management of monogenic diabetes in children and adolescents. Pediat Diabetes 2009; 10(Suppl 12): 33–42.
15. Shepherd M, Pearson ER, Houghton J, Salt G, Ellard S, Hattersley AT. No deterioration in glycemic control in HNF–1alpha maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas. Diabetes Care 2003; 26: 3191–3192.
16. Fajans SS, Brown MB. Administration of sulphonylureas can increase glucose-induced insulin secretion for decades in patients with maturity-onset diabetes of the young. Diabetes Care 1993; 16: 1254–1261.
17. Shepherd M, Shields B, Ellard S, Rubio-Cabezas O, Hattersley AT. A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet Med 2009; 26: 437–441.
18. Steele AM, Shields BM, Shepherd M, Ellard S, Hattersley AT, Pearson ER. Increased all-cause and cardiovascular mortality in monogenic diabetes as a result of mutations in the HNF1A gene. Diabet Med 2010; 27: 157–161.
19. Velho G, Vaxillaire M, Boccio V, Charpentier G, Froguel P. Diabetes complications in NIDDM kindreds linked to the MODY3 locus on chromosome 12q. Diabetes Care 1996; 19: 915–919.
20. Isomaa B, Henricsson M, Lehto M, Forsblom C, Karanko S, Sarelin L et al. Chronic diabetic complications in patients with MODY3 diabetes. Diabetologia 1998; 41: 467–473.
21. Owen KR, Thanabalasingham G, James TJ, Karpe F, Farmer AJ, McCarthy MI et al. Assessment of high-sensitivity C–reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations. Diabetes Care 2010; 33: 1919–1924.
22. Halban PA, Polonsky KS, Bowden DW, Hawkins MA, Ling C, Mather KJ et al. Beta–cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care 2014; 37: 1751–1758.
23. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986.
24. Skupien J, Gorczynska-Kosiorz S, Klupa T, Cyganek K, Wanic K, Borowiec M et al. Molecular background and clinical characteristics of HNF1A MODY in a Polish population. Diabetes Metab 2008; 34: 524–528.
25. Schober E, Rami B, Grabert M, Thon A, Kapellen T, Reinehr T et al. Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with Type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database. Diabet Med 2009; 26: 466–473.
26. Owen KR, Shepherd M, Stride A, Ellard S, Hattersley AT. Heterogeneity in young adult onset diabetes: aetiology alters clinical characteristics. Diabet Med 2002; 19: 758–761.
27. McDonald TJ, McEneny J, Pearson ER, Thanabalasingham G, Szopa M, Shields BM et al. Lipoprotein composition in HNF1A–MODY: differentiating between HNF1A–MODY and type 2 diabetes. Clin Chim Acta 2012; 413: 927–932.